Table 3A.
Antibody and IGRA titres two (T2) and six months (T3) after vaccination in the seroconverted pure vaccination cohort.
| Variable | Group | Category | Two months (T2) | Six months (T3) | p-value(Wilcoxon test) |
|---|---|---|---|---|---|
| Humoral responses | |||||
| IgA-Ab Spike S1 | MP | Median (interquartile range) | 9 (5·8–9) | 3·31 (1·5–5·9) | < 0·001 |
| IgA-Ab Spike S1 | DP | Median (interquartile range) | 7·87 (4·0–9) | 1·84 (0·8–4·3) | < 0·001 |
| IgA-Ab Spike S1 | KTR | Median (interquartile range) | 4·6 (2–9) | 1·8 (0·8–4·1) | < 0·001 |
| IgG-Ab Spike S1 | MP | Median (interquartile range) | 384 (384–384) | 351·1 (239–384) | < 0·001 |
| IgG-Ab Spike S1 | DP | Median (interquartile range) | 384 (384–384) | 192·9 (86–356) | < 0·001 |
| IgG-Ab Spike S1 | KTR | Median (interquartile range) | 329·8 (110·7–384) | 121·1 (51·8–295·6) | < 0·001 |
| RBD | MP | Median (interquartile range) | 99·33 (98·7–99·6) | 89 (79·2–95·9) | < 0·001 |
| RBD | DP | Median (interquartile range) | 98·1 (91·2–99·4) | 57·7 (24·8–84·9) | < 0·001 |
| RBD | KTR | Median (interquartile range) | 69·6 (38·3–95·5) | 40·1 (18·7–71·9) | < 0·001 |
| IGRA– T-cellular response | |||||
| IGRA | MP | Median (interquartile range) | 2282·1 (874·6–2487·7) | 554·6 (307·2–2461·5) | < 0·001 |
| IGRA | DP | Median (interquartile range) | 888·7 (270·4–2479) | 335·0 (79·5–1161·4) | < 0·001 |
| IGRA | KTR | Median (interquartile range) | 113·3 (14·3–326·4) | 48·0 (15·9–176·1) | 0·055 |
MP = Medical Personnel; DP = Dialysis Patients; KTR = Kidney Transplant Recipient; Interferon-γ release assay = IGRA;
This table compares the average titre levels (median/interquartile range) on T3 with T2 (different columns) for the different anti-Spike S1 IgA, IgG, RBD-IgG antibodies as well as for cellular immunity via IGRA measurements. For this evaluation, all participants with asymptomatic* or documented symptomatic** COVID-19 disease before and during vaccination up to T3 (six months) were excluded.
*Asymptomatic COVID-19 disease definition - neither knowledge nor symptoms of COVID-19 disease, but IgG-antibody reaction to nucleocapsid (T0, T2 or T3) or to the Spike protein subunit S1 (only T0) of the SARS-CoV-2 virus is positive.
**Symptomatic COVID-19 disease definition - SARS-CoV-2 PCR positive patients with clinical symptoms.